Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Triple-Negative Breast Cancer|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Mesothelioma|Fumarate Hydratase (FH)-Deficient Tumors|Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)|Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors|Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations|Tumors Harboring Amplifications in the cMyc Gene
Interventions: DRUG: CB-839|DRUG: Pac-CB|DRUG: CBE|DRUG: CB-Erl|DRUG: CBD|DRUG: CB-Cabo
Sponsor: Calithera Biosciences, Inc